NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016
Kenneth C. Anderson(Dana-Farber Cancer Institute), Rashmi Kumar(University of London), Leona Holmberg, Jason C. Chandler(West Cancer Center), Kelly Godby(University of Alabama at Birmingham), Benjamin Djulbegović(University of South Florida), Craig C. Hofmeister(The Ohio State University), George Somlo(City Of Hope National Medical Center), Shaji Kumar(Mayo Clinic), Djordje Atanackovic(University of Maryland, Baltimore), Cristina Gasparetto(Dana-Farber Cancer Institute), Seema Singhal(All India Institute of Medical Sciences), Adetola A. Kassim(Vanderbilt University), Noopur Raje(Massachusetts General Hospital), Frederic J. Reu(Deciphera Pharmaceuticals (United States)), Dorothy A. Shead(University of the Witwatersrand), Steven P. Treon(Dana-Farber Cancer Institute), Michaela Liedtke(Cancer Institute (WIA)), Melissa Alsina(Moffitt Cancer Center), Matthew A. Lunning(University of Nebraska Medical Center), Caitlin Costello(University of California San Diego), Carol Ann Huff(Sidney Kimmel Comprehensive Cancer Center), Sarah A. Holstein(University of Nebraska Medical Center), Keith Stockerl‐Goldstein(City Of Hope National Medical Center), Joachim Yahalom(Unknown)
Cited by 62
Related Papers
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
|New England Journal of Medicine|2003|2.6k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide
|Biology of Blood and Marrow Transplantation|2008|1.9k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k